Drugs Made In America Acquisition entered into a Definitive Merger Agreement to combine with Power Analytics Global, an AI, advanced analytics and quantum‑resistant security company. The deal targets a $1.0 billion enterprise value for PAGC, subject to milestones based on verified revenue contracts, with a $300 million floor valuation. Post‑closing, former PAGC holders are expected to own about 90% and DMAA shareholders about 10%, before any PIPE dilution. Closing is subject to customary conditions, Nasdaq listing approval, a minimum cash target of $30 million (flexible to not less than $15 million), and PAGC being debt‑free.
Agreement details:
- Agreement type: Definitive Merger Agreement (business combination)
- Counterparty: Power Analytics Global
- Signed / Effective: Apr 29 2026 / same
- Duration / Termination: Until closing
- Reason: Business combination to take PAGC public and build AI platform
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.